anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,240,130. Allergens. INSTITUT PASTEUR. 19 Sept., 1968 [26 Sept., 1967], No. 44535/68. Heading A5B. A method for the preparation of a slow release allergen comprises extracting the allergen from a powder which contains it by stirring the powder with an aqueous medium; separating the aqueous solution of the allergen, thus obtained, from the powder; precipitating the allergen from the solution by adding a neutral salt; separating the precipitate obtained; dissolving the precipitate again in water and adding an alumina gel to the water containing the dissolved precipitate. The extraction is suitably carried out using aqueous dibasic sodium phosphate and the precipitation by using ammonium sulphate. An antiseptic such as thimerosal may also be present. The allergens may be extracted from house dust, pollen, feathers, hair, scales, wool, mould, flour or kapok.
Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
The study will have 4 cohorts, consisting of participants with severe renal impairment who are not on dialysis (Cohort 1), moderate renal impairment (Cohort 2), mild renal impairment (Cohort 3) and participants with normal renal function (Cohort 4). Following completion of Cohort 1 and Cohort 4, pharmacokinetics (PK) and safety data will be reviewed and a decision will be made whether to study unmatched participants with moderate and mild renal impairment (Cohorts 2 and 3, respectively).

Participants will be screened up to 21 days before administration of study drug. Eligible participants will be admitted to the clinical unit either on the evening of Day -2 or on the morning of Day -1. Each participant will receive a single oral dose of the study drug under fasted conditions on Day 1. Participants will be required to remain resident in the clinical unit until the morning of Day 3 but, if participants prefer, may also remain resident until all PK and other study procedures are completed on Day 7. This decision to extend residency will be made at the discretion of the principal investigator. If participants do check out on Day 3, participants will then return to the unit, as scheduled, for collection of PK samples and safety assessments, with a final Follow-up Visit on Day 14.
Inflammatory and immune changes are an effect of some antisense oligonucleotide drugs, including TEGSEDI. In clinical studies, serious inflammatory and immune adverse reactions occurred in TEGSEDI-treated patients, including immune thrombocytopenia and glomerulonephritis, as well as a single case of antineutrophil cytoplasmic autoantibody (ANCA)-positive systemic vasculitis [see Warnings and Precautions (5.2) and (5.3)].

Neurologic Serious Adverse Reactions

In clinical studies, neurologic serious adverse reactions consistent with inflammatory and immune effects occurred in TEGSEDI-treated patients, in addition to stroke and carotid artery dissection [see Warnings and Precautions (5.5)]. Two months after the first TEGSEDI dose, one patient developed a change in gait that progressed over 6 months to paraparesis, in the absence of radiologic evidence of spinal cord compression. Another patient developed progressive lumbar pain, weight loss, headache, vomiting, and impaired speech 7 months after starting TEGSEDI. Cerebrospinal fluid analysis findings included elevated protein, a lymphocyte-predominant pleocytosis, and testing that was negative for infection. The patient recovered after empiric therapy (high-dose steroids, antibiotics) and resumed TEGSEDI without recurrence of symptoms.
An approach for prioritizing the review of medial image scans in a medical record review program may be provided. The approach may include analyzing one or more medical image, where each image scan is associated with a patient from a plurality of patients. The analysis of the medical image scan may be based on a machine learning algorithm. The approach may also include identifying an abnormal condition(s) from the analyzed medical scans, where the identified abnormal condition(s) is based on the analysis. The approach may further include prioritizing the identified abnormal condition(s) if the abnormal condition is an urgent condition. Additionally, the approach may include presenting a scaled down version of the prioritized medical scan within a mini viewer window within a medical record review program.
Participants will receive BC3195 at the RP2D identified in Phase 1a. Approximately 3 to 4 expansion cohorts will be enrolled using a Simon's 2-stage design. Expansion cohorts will focus on tumor types that may derive benefit from BC3195 treatment, including head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), breast cancer (BC), non-small cell lung cancer (NSCLC), endometrial cancer (EMC), urothelial cancer (UC), colorectal cancer (CRC), ovarian cancer (OC), pancreatic cancer, and prostate cancer.
Amyvid-PET scan will be performed. According to approved protocol for Alzheimer's disease diagnostics, 370MBq (10mCi) absorbed dose 7mSv of Amyvid will be introduced intravenously and 30-50 minutes after the PET images will be acquired.
Standard care (SC) for adolescents and young adults seen in outpatient CF clinics in Year 1 of the Study. CAP intervention during Year 2 of the Study.
The invention discloses a nonirritating mosquito-repellent itching-relieving dew for children and a preparation method thereof, and relates to the field related to children health care chemical preparations. The nonirritating mosquito-repellent itching-relieving dew for children comprises cortex of Chinese dittany root, golden larch bark, natural borneol, marigold essential oil, pelargonium graveolens (mozzie buster) essential oil, eucalyptus leaf essential oil, lemon-grass essential oil and polyethylene glycol (PEG)-400 as a solvent. The preparation method orderly comprises the following steps of Chinese herbal medicine ultrasonic extraction, concentration and preparation. The nonirritating mosquito-repellent itching-relieving dew for children utilizes natural materials having effects of repelling mosquitos, relieving itching and killing bacteria so that safety and high efficiency are realized. The nonirritating mosquito-repellent itching-relieving dew for children solves the problem that the chemosynthetic products for repelling insects and relieving itching damage skin. The nonirritating mosquito-repellent itching-relieving dew for children utilizes PEG-400 as a solvent for replacing the traditional irritant ethanol and really prevents stimulation on the skin. The preparation method does not use a hot reflux method and a decoction method used in the conventional traditional Chinese medicine extraction. The preparation method utilizes a modern supersonic extraction technology and has the advantages of short time, low energy consumption, high extraction ratio, low carbon, environmental friendliness and low cost.
Transient receptor potential vanilloid 1 (TRPV1), a ligand-gated cation channel, is a receptor for vanilloids on sensory neurons and is also activated by capsaicin, heat, protons, arachidonic acid metabolites, and inflammatory mediators on neuronal or non-neuronal cells. However, the role of the TRPV1 receptor in pro-inflammatory cytokine secretion and its potential regulatory mechanisms in lipopolysaccharide (LPS)-induced inflammation has yet to be entirely understood. To investigate the role and regulatory mechanism of the TRPV1 receptor in regulating LPS-induced inflammatory responses, bone marrow-derived macrophages (BMDMs) harvested from wild-type (WT) and TRPV1 deficient (Trpv1-/-) mice were used as the cell model. In WT BMDMs, LPS induced an increase in the levels of tumor necrosis factor-α, IL-1β, inducible nitric oxide synthase, and nitric oxide, which were attenuated in Trpv1-/- BMDMs. Additionally, the phosphorylation of inhibitor of nuclear factor kappa-Bα and mitogen-activated protein kinases, as well as the translocation of nuclear factor kappa-B and activator protein 1, were all decreased in LPS-treated Trpv1-/- BMDMs. Immunoprecipitation assay revealed that LPS treatment increased the formation of TRPV1-Toll-like receptor 4 (TLR4)-cluster of differentiation 14 (CD14) complex in WT BMDMs. Genetic deletion of TRPV1 in BMDMs impaired the LPS-triggered immune-complex formation of TLR4, myeloid differentiation protein 88, and interleukin-1 receptor-associated kinase, all of which are essential regulators in LPS-induced activation of the TLR4 signaling pathway. Moreover, genetic deletion of TRPV1 prevented the LPS-induced lethality and pro-inflammatory production in mice. In conclusion, the TRPV1 receptor may positively regulate the LPS-mediated inflammatory responses in macrophages by increasing the interaction with the TLR4-CD14 complex and activating the downstream signaling cascade.
OBJECTIVE: Negative MRI and an epileptogenic zone (EZ) adjacent to eloquent areas are two main issues that can be encountered during pre-surgical evaluation for epilepsy surgery. Focal Cortical Dysplasia type II (FCD type II) is the most common aetiology underlying a negative MRI. The objective of this study is to present three cases of pediatric patients exhibiting negative MRI and a seizure onset zone close to eloquent areas, who previously underwent traditional open surgery or SEEG-guided radiofrequency thermocoagulations (RF-TC). After seizure seizure recrudescence, pre-surgical SEEG was re-evaluated and Magnetic Resonance-guided laser interstitial thermal therapy (MRg-LiTT) was performed. We discuss the SEEG patterns, the planning of laser probes trajectories and the outcomes one year after the procedure.
METHODS: Pediatric patients who underwent SEEG followed by MRg-LiTT for drug-resistant epilepsy associated with FCD type II at our Centre were included. Pre-surgical videoEEG (vEEG), stereoEEG (sEEG), and MRI were reviewed. Post-procedure clinical outcome (measured by Engel score) and complications rates were evaluated.
RESULTS: Three patients underwent 3 MRg-LiTT procedures from January 2022 to June 2022. Epileptogenic zone was previously studied via SEEG in all the patients. All the three patients pre-surgical MRI was deemed negative. Mean age at seizure onset was 47 months (21-96 months), mean age at MRg-LiTT was 12 years (10 years 10 months - 12 years 9 months). Engel class Ia outcome was achieved in patients #2 and #3, Engel class Ib in patient #1. Mean follow-up length was of 17 months (13 months - 20 months). Complications occurred in one patient (patient #2, extradural hematoma).
CONCLUSIONS: The combined use of SEEG and MRg-LiTT in complex cases can lead to good outcomes both as a rescue therapy after failed surgery, but also as an alternative to open surgery after a successful SEEG-guided Radiofrequency Thermocoagulation (RF-TC). Specific SEEG patterns and a previous good outcome from RF-TC can be predictors of a favourable outcome.
Pregnancy Category C. In developmental toxicity studies in rabbits, oral treatment with sumatriptan combined with naproxen sodium (5/9, 25/45, or 50/90 mg/kg/day sumatriptan/naproxen sodium) or each drug alone (50/0 or 0/90 mg/kg/day sumatriptan/naproxen sodium) resulted in decreased fetal body weight in all treated groups and in increased embryofetal death at the highest dose of naproxen, alone and in combination with sumatriptan. Naproxen sodium, alone and in combination with sumatriptan, increased the total incidences of fetal abnormalities at all doses and increased the incidences of specific malformations (cardiac interventricular septal defect in the 50/90-mg/kg/day group, fused caudal vertebrae in the 50/0- and 0/90-mg/kg/day groups) and variations (absent intermediate lobe of the lung, irregular ossification of the skull, incompletely ossified sternal centra) in the 50/0- and 0/90-mg/kg/day groups. A no-effect dose for development toxicity in rabbits was not established. The lowest effect dose was 5/9 mg/kg/day sumatriptan/naproxen sodium, which was associated with plasma exposures (AUC) to sumatriptan and naproxen that were 1.4 and 0.14 times, respectively, those attained at the maximum recommended human oral daily dose of 85 mg sumatriptan and 500 mg naproxen sodium.

In previous developmental toxicity studies in rats and rabbits, oral treatment with sumatriptan was associated with embryolethality, fetal abnormalities, and pup mortality. Oral treatment of pregnant rats with sumatriptan during the period of organogenesis resulted in an increased incidence of fetal blood vessel (cervicothoracic and umbilical) abnormalities and decreased pup survival at doses of 250 mg/kg/day or higher. The highest no-effect dose was approximately 60 mg/kg/day, which is approximately 7 times the recommended human oral daily dose of 85 mg sumatriptan on a mg/m2 basis. Oral treatment of pregnant rabbits with sumatriptan during the period of organogenesis resulted in an increased incidence of cervicothoracic vascular and skeletal abnormalities at a dose of 50 mg/kg/day and embryolethality at 100 mg/kg/day. The highest no-effect dose for embryotoxicity in rabbits was 15 mg/kg/day, or approximately 3 times the recommended human oral daily dose of 85 mg sumatriptan on a mg/m2 basis.

Inhibitors of prostaglandin synthesis (including naproxen) are known to delay parturition. Because of this and the known effects of drugs of this class on the human fetal cardiovascular system (closure of the ductus arteriosus), use during third trimester should be avoided.

There are no adequate and well-controlled studies in pregnant women.

TREXIMET should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

Pregnancy Registry: To monitor fetal outcomes of pregnant women exposed to TREXIMET, GlaxoSmithKline maintains a TREXIMET Pregnancy Registry. Physicians are encouraged to register patients as soon as possible after they become pregnant and (if possible) before the outcome of the pregnancy is known by calling (800) 336-2176.
Participants with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-low will receive ARX788 intravenously over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants also undergo CT, PET/CT, and collection of blood samples throughout the study.
Stress urinary incontinence (SUI) affects about 26% of women between 30 and 59 years of age. It is the sudden involuntary urine leakage secondary to increased intra abdominal pressure related to physical activities as laughing, sneezing, straining, coughing, or exercising . There are two common mechanisms for SUI: urethral hypermobility due to loss of support of the bladder neck and urethra (affected by increased intra-abdominal pressure), and weakness of the urinary sphincter that may result from trauma, repeated urogynaecological surgeries, neurological disease, ageing or diseases leading to systemic muscular atrophy. SUI is the most common pelvic floor dysfunction linked to the vaginal delivery. However the prevalence of stress incontinence peaks occurs in the fifth decade of life . and all types of incontinence are commonly occurring with ageing and obesity.

Urethral hypermobility means that the proximal part of the urethra may exhibit a rotational movement in a postero-inferior direction. And it was diagnosed when the urethra rotated during strain over 30° from its resting axis . Urethral rotation angles may assist in both assessment and diagnosis of patients with SUI, which may in turn decreases requires for any other investigations .The ultrasonography assessment of the angle of inclination (α angle: the angle between the axis of the proximal urethra and the central axis of the symphysis pubis) and posterior urethrovesical angle (β angle: the angle between the proximal urethra and the posterior vesical wall) has been investigated by several researchers. However, recently transperineal ultrasonography is a practical, reliable, non-invasive and comfortable method for evaluation of SUI. Additionally, it has the advantage of dynamic evaluation during the Valsalva maneuver .

Urinary sphincter composed of; internal urethral sphincter that is predominantly smooth muscle without voluntary control, and the external urethral sphincter and pelvic floor muscles (PFMs) that are predominantly striated muscle with voluntary control. During activities the PFMs contract to prevent the leakage of urine, in addition, they play a significant role in trunk stabilization through its connections with abdominal muscles, diaphragm, and gluteus by myofascial continuity . Contractions of PFMs lead to activation of gluteal muscles especially the levator ani through their connection by the fossa ischioanalis . Additionally, rotators mainly the internal obturator and piriformis muscles are important for maintaining pelvic stability and PFM functionality .Moreover, the tension of the rotator cuff and gluteal muscles is also primarily determined by position of the foot. So, the tension of PFM may affect the tension and functioning of the rotators and gluteal muscles, thus influencing the biomechanics and position of whole lower limb even the foot position .
Participants received talimogene laherparepvec at an initial dose of up to 4 mL 10⁶ plaque-forming units (PFU)/mL by intralesional injection. Subsequent doses of talimogene laherparepvec at up to 4 mL of 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until disappearance of injectable lesions, complete response (CR), confirmed disease progression (PD) per modified Immune-related Response Criteria (irRC), intolerance of study treatment, 24 months from the date of the first dose of pembrolizumab, or end of study, whichever occurred first. Participants also received 200 mg pembrolizumab administered intravenously every 2 weeks starting at the time of the third dose of talimogene laherparepvec (week 6) until confirmed PD per modified irRC, treatment intolerance, 24 months from the first dose, or end of study, whichever occurred first.
This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have no plaque and an Agatston score of "0". They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into "No atherosclerosis/endothelial function normal" and "No atherosclerosis/endothelial function abnormal". Blood will then be collected for metabolomics, lipidomic and whole genome sequencing.
There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz sham TMS will be delivered to the inferior pars triangular. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
Home environs-based lifestyle counseling Involves Spanish-speaking community health workers interacting with intervention subjects in home visits and phone calls - 12 contacts overall. The counseling focuses on promoting subject adherence to the Dietary Guidelines for Americans (DGA) and the Physical Activity Guidelines for Americans (PAGA) with special attention devoted to changing the home environment to make it optimally supportive of the lifestyle choices consistent with the DGA and PAGA. Study participants will also be provided 4 group education sessions that will be devoted to improving subject adherence to the DGA and PAGA.
In an approach to dynamic seating adjustment, a computer monitors a multi-seating arrangement. A computer identifies one or more users, each in a seat of the multi-seating arrangement. A computer retrieves a user profile associated with each of the one or more users. A computer receives data from one or more sensors. A computer creates an ergonomic digital twin model for each of the one or more users based on the associated user profile and the received sensor data. Based on the ergonomic digital twin model, a computer creates a simulation of an experience of each of the one or more users. Based on the simulation, a computer predicts discomfort associated with sitting in the seat of the multi-seating arrangement is expected for one or more of the one or more users. A computer adjusts a configuration of the respective seat of the one or more users.
The present invention relates to an immune balancing and energy restoring pill a preparation method thereof. Raw medical materials of arnebia root, rhubarb, immature orange fruit, glabrous sarcandra herb, cremastra, cordrceps, magnolia bark, rhiizoma dioscorea from Hena of China, angelica and zedoray rhizome are adopted. The raw materials are divided into three groups for grinding and sifting according to proportion by weight. The three groups of the powdered medicines are fully stirred, added with medical starch, and is fully stirred. The medicine is rolled into a tablet by a flaker. The medicine quality standards of the present invention are all in accordance with the requirement of the specification in The Chinese Pharmacopoeia. Toxicity tests verify that the medicine has no obvious toxic reaction and basically has no toxicity. The present invention relates to an immune balancing and energy restoring pill, has reasonable prescription, simple preparation, pure Chinese medicines and convenient medicine taking, solve the expensive medical cost for curing cancer, and is suitable for people with different kinds of cancer and people with cancer in different stages. The forfeited life index of patients with primary liver cancer is restored, and the lives are prolonged by 17 months on average; the lives of patients with lung cancer are prolonged by 28 months on average; the lives of patients with nasopharyngeal cancer are prolonged by 28 months on average.
Application in the Preoperative Period: Before the surgery, HTBF and SAS will be applied to both groups and pain assessment will be made once. In addition, the intestinal functions of both groups will be questioned and recorded during each procedure. TENS will not be applied to the control group, and to the TENS group, 11.,-23.,-35.,-47. TENS will be applied a total of 4 times for 20 minutes between hours. There will be no intervention in the routine analgesic application of the clinic for both groups.